Skip to main content
Premium Trial:

Request an Annual Quote

Evotec, Celmatix Partner on Women's Reproductive Health Drug Discovery

NEW YORK — Evotec and Celmatix said today that they have formed a drug-discovery partnership focused on prevalent but underserved women's reproductive health conditions including polycystic ovary syndrome, endometriosis, and infertility.

Under the terms of the alliance, Hamburg, Germany-based Evotec will be responsible for medicinal chemistry and in vitro and in vivo pharmacology activities. Celmatix — which recently launched a division to discover therapeutics for women's health indications including reproductive disorders — will contribute to drug-discovery efforts using its Reproductive Atlas platform, which combines biological annotations from peer-reviewed literature with genomic data associated with lifestyle, diet, environment, and reproductive outcomes.

Additional terms were not disclosed.

"Through combining our vast datasets and deep expertise in women's health with Evotec's proven experience in therapeutic discovery, we are poised to catalyse real change and finally provide women therapies they deserve," Piraye Yurttas Beim, founder and CEO of New York City-based Celmatix, said in a statement.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.